Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

NCT07389941 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide, given before a heart procedure called catheter ablation, can help reduce irregular heart rhythms in adults with atrial fibrillation.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 240 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-10 · est. completion 2029-04

What this study is testing ClinicalTrials.gov NCT07389941 ↗

Description as written by the study sponsor.

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Treatments tested

Semaglutide (SEMA) Drug

Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)

Main thing measured	Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)
Sponsor	University of Luebeck
Conditions studied	Atrial Fibrillation (AF)
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07389941 ↗